MedPath

Evaluation for antiatherogenic efficacy of febuxostat in patients with hyperuricemia

Not Applicable
Conditions
Hyperuricemia
Registration Number
JPRN-UMIN000009134
Lead Sponsor
Department of Medicine and Bioregulatory Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1) known allergic reaction by febuxostat 2) severe renal and/or liver disease 3) pregnant women 4) inadequate candidate at a physician's discretion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of carotid atherosclerosis
Secondary Outcome Measures
NameTimeMethod
serum uric acid levels
© Copyright 2025. All Rights Reserved by MedPath